Novartis loses bid to block US Entresto generic through 2026 By Blake Brittain July 11, 202510:10 AM PDTUpdated July 11, 2025 ...

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.

Novartis (NVS) stock slips as the company lost its bid to block MSN Pharma's generic Entresto launch after a U.S. judge ruled against its injunction. Read more here.

Entresto brought in $7.8 billion in 2024, accounting for around 15% of the company's overall global sales.